Professor Anton Hagenbeek 1948–2021: Father of MRD and lymphoma expert - Takeaways - MDSpire

Professor Anton Hagenbeek 1948–2021: Father of MRD and lymphoma expert

  • By

  • Bob Löwenberg

  • Marie José Kersten

  • Robert Peter Gale

  • Marinus van Oers

  • July 19, 2021

  • 0 min

Share

  • 1

    Professor Anton Hagenbeek was a prominent figure in hematology, known for his contributions to minimal residual disease (MRD) and lymphoma research.

  • 2

    He received his MD from Erasmus University in 1972 and completed a PhD focused on extracorporeal irradiation of blood in leukemia models.

  • 3

    Hagenbeek played a key role in establishing pivotal clinical trials for lymphoma therapies, including rituximab and brentuximab vedotin.

  • 4

    He was dedicated to patient well-being, developing an e-health program to help cancer patients manage fatigue.

  • 5

    Hagenbeek's legacy includes his roles in the European Hematology Association and his impact on the field through teaching and research.

Original Source(s)

Professor Anton Hagenbeek 1948–2021: Father of MRD and lymphoma expert

  • by Bob Löwenberg, Marie José Kersten, Robert Peter Gale, Marinus van Oers

  • July 19, 2021

Related Content

Home-Based Monitoring Could Transform Care for Patients Receiving T-Cell Redirecting Therapies

A study found that outpatient observation cut hospital stays dramatically, with no adverse safety events reported. It also freed up inpatient beds and cut healthcare costs.

  • by

  • January 9, 2026

  • 4 min
Analysis of the Frequency and Outcomes of Transformed Nodular Lymphocyte-Predominant Hodgkin Lymphoma in the United States: A Population-Based Study

Primary amelanotic leptomeningeal melanocytosis mimicking subarachnoid hemorrhage: a case report of the deceptive masquerader